drugset
drugset / Trial / NCT06182358

Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

NCT06182358 ↗

Phase 4 Completed 145 enrolled Tarsus Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.

Timeline

Start
2023-12-27
Primary completion
2025-01-27
Completion
2025-01-27

Drugs

EvaluationDrugModalityDoseRoute
Subject lotilaner Small molecule 0.25 % Topical

Indications

parasitic eyelid infestation